T cell receptor transgenic lymphocytes infiltrating murine tumors are not induced to express foxp3

Journal of Hematology and Oncology

Volumn 4, Issue , 2011, Pages

  Quatromoni, Jon G ^a   Morris, Lilah F ^a   Donahue, Timothy R ^a   Wang, Yue ^a   McBride, William ^a   Chatila, Talal ^a   Economou, James S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; OVALBUMIN; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; LYMPHOCYTE SUBPOPULATION; MELANOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPLEEN CELL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR XENOGRAFT; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; DISEASE MODEL; EXPERIMENTAL MELANOMA; FEMALE; GENETICS; IMMUNOLOGY; MALE; METHODOLOGY; PATHOLOGY; REGULATORY T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 81555237059     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-4-48     Document Type: Article

References (48)

1. Regulatory T cells in tumor immunity. Nishikawa H, Sakaguchi S, Int J Cancer 2010 127 4 759 67
2. Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. Lahl K, et al. J Exp Med 2007 204 1 57 63 (Pubitemid 46148756)
3. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Fontenot JD, Gavin MA, Rudensky AY, Nat Immunol 2003 4 4 330 6 (Pubitemid 36432314)
4. Control of regulatory T cell development by the transcription factor Foxp3. Hori S, Nomura T, Sakaguchi S, Science 2003 299 5609 1057 61 (Pubitemid 36222930)
5. T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells. Fahlen L, et al. J Exp Med 2005 201 5 737 46 (Pubitemid 40395119)
6. Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. Collison LW, et al. J Immunol 2009 182 10 6121 8
7. A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood. Yamagiwa S, et al. J Immunol 2001 166 12 7282 9 (Pubitemid 32525603)
8. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. Fantini MC, et al. J Immunol 2004 172 9 5149 53 (Pubitemid 38542009)
9. Emerging concepts in CD8(+) T regulatory cells. Niederkorn JY, Curr Opin Immunol 2008 20 3 327 31
10. Peptide-specific CD8 T regulatory cells use IFN-gamma to elaborate TGF-beta-based suppression. Myers L, et al. J Immunol 2005 174 12 7625 32 (Pubitemid 40806267)
11. CD8+ Foxp3+ T cells share developmental and phenotypic features with classical CD4+ Foxp3+ regulatory T cells but lack potent suppressive activity. Mayer CT, et al. Eur J Immunol 2011 41 3 716 25
12. Revival of CD8+ Treg-mediated suppression. Smith TR, Kumar V, Trends Immunol 2008 29 7 337 42
13. Inhibition of follicular T-helper cells by CD8(+) regulatory T cells is essential for self tolerance. Kim HJ, et al. Nature 2010 467 7313 328 32
14. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. Liyanage UK, et al. J Immunol 2002 169 5 2756 61 (Pubitemid 34921025)
15. Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Somasundaram R, et al. Cancer Res 2002 62 18 5267 72 (Pubitemid 35024601)
16. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Ichihara F, et al. Clin Cancer Res 2003 9 12 4404 8 (Pubitemid 37248397)
17. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Sasada T, et al. Cancer 2003 98 5 1089 99 (Pubitemid 37022112)
18. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Ormandy LA, et al. Cancer Res 2005 65 6 2457 64
19. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Woo EY, et al. Cancer Res 2001 61 12 4766 72 (Pubitemid 32691889)
20. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. Viguier M, et al. J Immunol 2004 173 2 1444 53 (Pubitemid 38924326)
21. Association of increased levels of heavy-chain ferritin with increased CD4+ CD25+ regulatory T-cell levels in patients with melanoma. Gray CP, Arosio P, Hersey P, Clin Cancer Res 2003 9 7 2551 9 (Pubitemid 36842096)
22. Positive and negative influences of regulatory T cells on tumour immunity. Gallimore AM, Simon AK, Oncogene 2008 27 45 5886 93
23. The impact of regulatory T cells on carcinogen-induced sarcogenesis. Betts G, et al. Br J Cancer 2007 96 12 1849 54 (Pubitemid 46912032)
24. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Badoual C, et al. Clin Cancer Res 2006 12 2 465 72 (Pubitemid 43166137)
25. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Curiel TJ, et al. Nat Med 2004 10 9 942 9 (Pubitemid 39273735)
26. Regulatory T cells dynamically control the primary immune response to foreign antigen. Haribahi D, et al. J Immunol 2007 178 2961 72
27. Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Vo DD, et al. Cancer Res 2009 69 8693 9
28. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Gobert M, et al. Cancer Res 2009 69 2000 9
29. Regulatory T cell development in the absence of functional Foxp3. Lin W, et al. Nat Immunol 2007 8 359 68 (Pubitemid 46745411)
30. Natural versus adaptive regulatory T cells. Bluestone JA, Abbas AK, Nat Rev Immunol 2003 3 3 253 7 (Pubitemid 37323210)
31. Molecular mechanisms of regulatory T cell development. Chatila T, J Clin Immunol 2008 28 6 625 30
32. Natural and TGF-beta-induced Foxp3(+)CD4(+) CD25(+) regulatory T cells are not mirror images of each other. Horwitz DA, Zheng SG, Gray JD, Trends Immunol 2008 29 9 429 35
33. A kinetic and dynamic analysis of Foxp3 induced in T cells by TGF-beta. Selvaraj RK, Geiger TL, J Immunol 2007 179 2 11. following 1390.
34. IL-2 is essential for TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. Zheng SG, et al. J Immunol 2007 178 4 2018 27
35. TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes. Peng Y, et al. Proc Natl Acad Sci USA 2004 101 13 4572 7 (Pubitemid 38437452)
36. Trafficking of FoxP3+ regulatory T cells: myths and facts. Kim CH, Arch Immunol Ther Exp (Warsz) 2007 55 3 151 9 (Pubitemid 46953945)
37. CCR4 as a novel molecular target for immunotherapy of cancer. Ishida T, Ueda R, Cancer Sci 2006 97 11 1139 46 (Pubitemid 44430638)
38. Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. Wei S, et al. Cancer Res 2007 67 15 7487 94 (Pubitemid 47206578)
39. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Kryczek I, et al. Cancer Res 2005 65 2 465 72
40. CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. Mizukami Y, et al. Int J Cancer 2008 122 10 2286 93 (Pubitemid 351542333)
41. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Shevach EM, Immunity 2009 30 5 636 45
42. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Bettelli E, et al. Nature 2006 441 7090 235 8
43. IL-23 promotes tumour incidence and growth. Langowski JL, et al. Nature 2006 442 7101 461 5 (Pubitemid 44264796)
44. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Sharma S, et al. Cancer Res 2005 65 12 5211 20 (Pubitemid 40827331)
45. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Curti A, et al. Blood 2007 109 7 2871 7 (Pubitemid 46482083)
46. Transforming growth factor-beta and T-cell-mediated immunoregulation in the control of autoimmune diabetes. You S, et al. Immunol Rev 2006 212 185 202 (Pubitemid 44116709)
47. Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer. Moo-Young TA, et al. J Immunother 2009 32 1 12 21
48. Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma. Liyanage UK, et al. J Immunother 2006 29 4 416 24 (Pubitemid 44288954)